Odronextamab
- Generic Name
- Odronextamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801338-64-6
- Unique Ingredient Identifier
- 8R5CM46UIO
- Background
Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma (NHL). Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however...
- Associated Conditions
- -
- Associated Therapies
- -
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
- Conditions
- Interventions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT06735664
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 216
- Registration Number
- NCT06230224
- Locations
- 🇨🇳
Chang Gung Memorial Hospital Kaohsiung, Kaohsiung City, Taiwan
🇹🇷VM Medical Park Mersin Hospital, Mezitli, Mersin, Turkey
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 470
- Registration Number
- NCT06149286
- Locations
- 🇩🇪
Clinic Frankfurt (Oder), Frankfurt, Hesse, Germany
🇹🇷Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 733
- Registration Number
- NCT06097364
- Locations
- 🇨🇱
Hospital Clinico Universidad de Los Andes, Santiago, Las Condes, Chile
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 904
- Registration Number
- NCT06091865
- Locations
- 🇫🇷
Hopital Saint Vincent-de-Paul, Lille, Nord, France
🇰🇷St. Vincent Hospital - The Catholic University of Korea, Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Yeouido St. Marys Hospital, Seoul, Korea, Republic of
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 478
- Registration Number
- NCT06091254
- Locations
- 🇪🇸
Hospital Clinico Universitario Valencia, Valencia, Spain
🇪🇸Hospital Universitary and Politecnic La Fe, Valencia, Spain
🇨🇭Kantonsspital Baden, Baden, Aargau, Switzerland
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 210
- Registration Number
- NCT05991388
- Locations
- 🇬🇧
Bristol Royal Hospital for Children, Bristol, United Kingdom
🇬🇧Royal Manchester Children's Hospital, Manchester, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham, United Kingdom
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 91
- Registration Number
- NCT05685173
- Locations
- 🇫🇷
Hopital Saint-Louis, Paris, Cedex 10, France
🇪🇸Hospital Vall d'Hebron, Barcelona, Spain
🇺🇸Rutgers Cancer Institute of New Jersey., New Brunswick, New Jersey, United States
A Compassionate Use (CU) Program of Odronextamab
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT05619367
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 576
- Registration Number
- NCT03888105
- Locations
- 🇺🇸
Tufts Cancer Center, Boston, Massachusetts, United States
🇨🇳Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Wuhan Hubei Province, China
🇨🇳Second Affiliated Hospital of Army Medical University, PLA, Chongqing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.